Nguyen Thi Viet Ha, Bengtsson Carina, Nguyen Gia Khanh, Hoang Thi Thu Ha, Phung Dac Cam, Sörberg Mikael, Granström Marta
Unit of Clinical Microbiology, Department of Microbiology, Tumor and Cell Biology (MTC) Karolinska Institutet and Clinical Microbiology, Karolinska University Hospital, Solna, Sweden.
Helicobacter. 2008 Dec;13(6):550-6. doi: 10.1111/j.1523-5378.2008.00628.x.
Eradication of Helicobacter pylori infection in children in developing countries needs further investigations upon which to base treatment recommendations. The aim of the study was to compare two 2-week triple therapies in a randomized double-blind trial.
In order not to exceed recommended dosages, the 238 H. pylori-infected children, aged 3 to 15 years (mean 8.6), were divided in two weight categories receiving at weights 13-22 kg: lansoprazole 15 mg once-daily and amoxicillin 500 mg twice-daily with metronidazole 250 mg twice-daily or clarithromycin 250 mg once-daily; at weights 23-45 kg: lansoprazole 15 mg and amoxicillin 750 mg with metronidazole 500 mg or clarithromycin 250 mg, all administered twice daily. H. pylori status was assessed by culture and a monoclonal-based antigen-in-stool test (Premier Platinum HpSA PLUS) and side effects by structured questionnaires.
The overall per-protocol eradication (n = 233) was similar in the two treatment regimens, 62.1% for the metronidazole and 54.7% for the clarithromycin-containing therapy. Eradication rate was higher in children >or= 23 kg (70.9%) than in children < 23 kg (45.7%). In children >or= 23 kg (n = 117) that received twice-daily administration of all drugs, efficacy of the metronidazole and clarithromycin-containing treatments were 69.5% and 72.4%, respectively.
The two treatments gave similar eradication rates. Significant differences for both treatments were found by weight, which could be the result of the once-daily proton pump inhibitor and clarithromycin and/or more antibiotic resistant strains in younger children.
发展中国家儿童幽门螺杆菌感染的根除治疗需要进一步研究以作为治疗建议的依据。本研究的目的是在一项随机双盲试验中比较两种为期2周的三联疗法。
为了不超过推荐剂量,将238名3至15岁(平均8.6岁)的幽门螺杆菌感染儿童按体重分为两类,体重13 - 22千克的儿童:兰索拉唑15毫克每日一次,阿莫西林500毫克每日两次加甲硝唑250毫克每日两次,或克拉霉素250毫克每日一次;体重23 - 45千克的儿童:兰索拉唑15毫克和阿莫西林750毫克加甲硝唑500毫克或克拉霉素250毫克,均每日两次给药。通过培养和基于单克隆抗体的粪便抗原检测(Premier Platinum HpSA PLUS)评估幽门螺杆菌感染状况,并通过结构化问卷评估副作用。
两种治疗方案的总体符合方案根除率(n = 233)相似,甲硝唑治疗组为62.1%,含克拉霉素治疗组为54.7%。体重≥23千克的儿童根除率(70.9%)高于体重<23千克的儿童(45.7%)。在体重≥23千克(n = 117)且所有药物每日两次给药的儿童中,含甲硝唑和含克拉霉素治疗的疗效分别为69.5%和72.4%。
两种治疗的根除率相似。两种治疗在体重方面均存在显著差异这可能是由于每日一次的质子泵抑制剂和克拉霉素以及/或年幼儿童中更多抗生素耐药菌株导致的。